<DOC>
	<DOCNO>NCT00524537</DOCNO>
	<brief_summary>The purpose Registry study evaluate long-term safety effectiveness adalimumab CD subject treat recommended product label .</brief_summary>
	<brief_title>A Long-Term Registry Humira® ( Adalimumab ) Subjects With Moderately Severely Active Crohn 's Disease ( CD )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects newly prescribe HUMIRA® ( adalimumab ) therapy ( never treat adalimumab ) participant Abbvie sponsor investigational Crohn 's disease ( CD ) trial , currently receive adalimumab treat physician make decision continue adalimumab therapy beyond duration investigational trial . Subjects participant AbbVie sponsor investigational Crohn 's CD trial , dose interruption since last dose study drug , Investigator provide source documentation dose information . Subjects currently receive adalimumab , per local approve label , dose interruption since induction dose adalimumab Investigator provide source documentation dose information . Subjects willing consent data collect provided AbbVie . Subjects capable willing give write informed consent comply requirement Registry study protocol . Subjects enrol treated accordance local product label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>